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Cells employ several modes of communication, from direct contact to paracrine signaling. Under-
standing what they are whispering one to another has long been a goal for immunologists. In this
scenario, the potential of a newly discovered way of sending specific messages between cell types,
extracellular vesicles (EVs), has started a revolution in the field.
During recent years, research on EVs has provided new insights into the pathophysiology of
several diseases. EVs are membrane-bound particles secreted by almost all cell types. Depending
on their biogenesis and size, they include exosomes, microparticles/microvesicles, and apoptotic
bodies (1). Characteristically, EVs carry markers from the source cell membrane and contain
genetic material, lipids, and proteins. They are known to play a role in cell-to-cell commu-
nication and to produce genotypic and phenotypic modifications in the target cell including
antigen presentation, apoptosis induction, cellular activation, and differentiation (2). In partic-
ular, elevated concentrations of EVs have been found in many diseases including cancer (3),
and autoimmune (4) and cardiovascular diseases (5). Most research on EVs is focused on their
characterization, identifying mechanisms of action, and their potential use as biomarkers, with
some studies investigating therapeutic applications. In relation to the promising results obtained
in the EV field; however, there are some technical issues concerning standardization to be
resolved and these are being addressed by researchers. Further, even though EVs have a growing
future as biomarkers, drug delivery systems, or therapeutic targets, there remain milestones to be
achieved on the path to their clinical application. This research topic aims to provide a forum
for the discussion of current and novel clinical applications of EVs, opening new avenues in this
field.
We focus the topic on two closely related fieldswhere EVs have produced themost impact, namely,
cancer and immunology. First, de Toro et al. have summarized the current roles of EVs in physio-
logical and pathological and physiological states, including neurodegenerative, cardiovascular, and
immune diseases (6). They conclude with an interesting section on the potential applications of EVs
in diagnosis and therapy.
In relation to cancer, Benito-Martín et al. have reviewed the functions of innate immune-derived
EVs in relation to modification of microenvironment and the control of tumor progression (7). The
authors also provide a detailed description of the role of EVs derived from innate immune cells in
specific cancers (colorectal cancer, osteosarcoma, neuroblastoma, and neurofibromatosis-1-related
tumors). They point to the lack of information on these EVs under physiological conditions.
The proposal suggested byCarvalho andOliveira is the use of EVs as a “liquid biopsy” overcoming
the limited information provided by a single fragment of a tumor (8). They also assert that EVs
may be circulating biomarkers with a potential role in the detection of the early stages of cancer.
However, they note that the identification of EVs and characterization of their cargo should be
carefully analyzed depending on whether they have been isolated in a human cancer sample or in a
cancer cell-line culture. Finally, they propose a longitudinal approach involving the sampling of EVs
over the course of a disease.
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Moving specifically to the biomarker area, Gámez-Valero et al.
have conducted a comprehensive review of urine-derived EV can-
didates for monitoring kidney diseases (9). These authors affirm
that urinary EVs reflect the state of urinary system; however,
depending on the isolation protocol used, published data are not
always comparable. In relation to this, they detail current and
some novel methods for isolating EVs from urine and provide a
clear review of urinary EV biomarkers by type of kidney disease.
They also stress the urgent need for a consensus on methods and
for these to then be applied to larger cohorts.
In an attempt to respond to the aforementioned suggestion,
Sáenz-Cuesta et al. have compared five different EV isolation
protocols (including the standard ultracentrifugation approach),
starting with blood and urine samples as these are the most
readily available, and several types of analysis (flow cytometry,
nanoparticle tracking analysis, and electronic microscopy, among
others) (10). The authors propose an interesting workflow for the
study of EVs in a hospital setting, taking into account the facilities
of a non-specialized core laboratory and based on an easy and
quick medium-speed centrifugation protocol.
The application of the study of EVs in a daily clinical setting
requires suitable technologies and quality controls that could be
managed by the hospital itself or delegated to specific facilities.
Regarding the facilities provided by culture platforms, Aiastui
posit that they should offer a basic level of quality control for the
production of large quantities of EVs in goodmanufacturing prac-
tice conditions (11). For that, close collaboration between clini-
cians from hospitals, the biotech industry, and basic researchers is
necessary to turn what is currently an idea into a product. As an
example, Aiastui suggest that according to current requirements,
culture platforms should become EV sample quality control ser-
vices before EV products are applied as a therapy.
Research into EV cargo is continuously growing thanks to
the spread of these new technologies. One of the most recently
applied omic approaches, metabolomics, is focused on metabo-
lites, cytosolic small molecules up to 1 kDa. Palomo et al. analyze
the benefits of adding this to the spectrum of omic approaches
applied to EVs, discussing which platform is the most suitable
and also warning about the importance of additional background
controls (e.g., exosome-depleted media analysis) (12).
Finally, Romagnoli et al. hypothesize about the possibility of
using dendritic cell (DC)-derived EVs as cancer immunotherapy
enhancing tumor antigenicity (13). They demonstrate the boost
effect of DC-derived EVs in primed T-cell activation against
an adenocarcinoma cell line and conclude that both DCs and
tumor cells became more immunogenic after the incorporation
of specific EVs.
It is the desire of the editors that this topic should help to
connect all interested authors and readers, and join our efforts to
understand what and how the cells are whispering.
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